Biofrontera Inc. Announces Enrollment of First Subject in Phase 2b Clinical Trial Evaluating Ameluz® + BF-RhodoLED® in Moderate-to-Severe AcneGlobeNewsWire • 12/13/21
Biofrontera Inc. Announces Notice of Allowance for U.S. Method-of-Use Patent on PDT-lampGlobeNewsWire • 12/08/21
Biofrontera Inc. Enrolls First Subject in Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz®GlobeNewsWire • 12/06/21
Biofrontera Inc. Announces Notice of Allowance for U.S. Patent on Innovative Illumination ProtocolGlobeNewsWire • 12/02/21
Biofrontera Inc. Reports Third Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 11/30/21
Biofrontera Inc. Pricing of $15 Million Private Placement Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 11/29/21
Biofrontera Inc. to Report Third Quarter Financial Results on November 30, 2021GlobeNewsWire • 11/23/21
Biofrontera Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional WarrantsGlobeNewsWire • 11/02/21